Quick Answer
Beam Therapeutics Inc. reported Total Revenue of $139.74 million for the year ending 2025.
- Beam Therapeutics Inc. showed an increase of +120.0% in Total Revenue from 2024 to 2025.
- This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $6.0 thousand | Q3 2019: $6.0 thousand | Q1 2020: $6.0 thousand | Q2 2020: $6.0 thousand | Q2 2020: $6.0 thousand | Q3 2020: $6.0 thousand | Q3 2020: $6.0 thousand | Q1 2021: $6.0 thousand | Q1 2021: $6.0 thousand | Q2 2021: $6.0 thousand | Q3 2021: $763.0 thousand | Q1 2022: $8.43 million | Q2 2022: $16.65 million | Q3 2022: $15.80 million | Q1 2023: $24.21 million | Q2 2023: $20.12 million | Q3 2023: $17.19 million | Q1 2024: $7.41 million | Q2 2024: $11.77 million | Q3 2024: $14.27 million | Q1 2025: $7.47 million | Q2 2025: $8.47 million | Q3 2025: $9.70 million.
- Over the full 9 years of available data (2019 to 2025), Beam Therapeutics Inc.'s Total Revenue has grown by 776,250.0%.
- Historical annual values: Fiscal year 2025: $139.74 million | Fiscal year 2024: $63.52 million | Fiscal year 2023: $377.71 million | Fiscal year 2022: $60.92 million | Fiscal year 2021: $51.84 million | Fiscal year 2020: $24.0 thousand | Fiscal year 2020: $24.0 thousand | Fiscal year 2019: $18.0 thousand | Fiscal year 2019: $18.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: